Mazdutide for Weight Management and Gout in Adults With Obesity
NCT07824895 on ClinicalTrials.gov · last registry update 2026-09-17
A small phase 4 — 30 participants, against a typical 75. Due to report 31 December 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Annualized Flare Rate (AFR). Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- mazdutide
- Sponsor
- Hongwei Jiang
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2026-09-15
- Primary completion
- 2027-12-31 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-17 | First seen in registry | Registered as NOT_YET_RECRUITING, P4 |
Primary outcome
Annualized Flare Rate (AFR)
Conditions studied
Gout · Obesity (BMI>30) · Hyperuricemia · Metabolic Syndrome
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.